Desirability and feasibility of a vaccine against cytomegalovirus.

Publication of a report from the Institute of Medicine in 2000 showing that a vaccine against cytomegalovirus (CMV) would likely be cost saving was very influential and encouraged the clinical evaluation of candidate vaccines. The major objective of a CMV vaccination program would be to reduce disease caused by congenital CMV infection, which is the leading viral cause of sensorineural hearing loss and neurodevelopmental delay. CMV has challenges as a vaccine target because it is a herpesvirus, it persists lifelong despite host immunity, infected individuals can be reinfected with new strains, overt disease occurs in those with immature or impaired immune systems and persons with this infection do not usually report symptoms. Nevertheless, natural immunity against CMV provides some protection against infection and disease, natural history studies have defined the serological and molecular biological techniques needed for endpoints in future clinical trials of vaccines and CMV is not highly communicable, suggesting that it may not be necessary to achieve very high levels of population immunity through vaccination in order to affect transmission. Three phase 2 CMV vaccine studies have been completed in the last 3 years and all report encouraging outcomes. A key international meeting was organized by the Food and Drug Administration in January 2012 at which interested parties from regulatory bodies, industry and academia discussed and prioritised designs for phase 2 and phase 3 clinical trials. Vaccines able to prevent primary infection with CMV and to boost the immune response of those already infected are desirable. The major target populations for a CMV vaccine include women of childbearing age and adolescents. Toddlers represent another potential population, since an effect of vaccine in this age group could potentially decrease transmission to adults. In addition, prospective recipients of transplants and patients with AIDS would be expected to benefit.
AuthorsPaul Griffiths, Stanley Plotkin, Edward Mocarski, Robert Pass, Mark Schleiss, Philip Krause, Stephanie Bialek
JournalVaccine (Vaccine) Vol. 31 Suppl 2 Pg. B197-203 (Apr 18 2013) ISSN: 1873-2518 [Electronic] Netherlands
PMID23598482 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Cytomegalovirus Vaccines
  • Clinical Trials as Topic
  • Cytomegalovirus Infections (prevention & control)
  • Cytomegalovirus Vaccines (therapeutic use)
  • Disease Transmission, Infectious (prevention & control)
  • Female
  • Humans
  • Pregnancy
  • Pregnancy Complications, Infectious (prevention & control)
  • Randomized Controlled Trials as Topic
  • United States
  • United States Food and Drug Administration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: